Michael Celano - 22 Jan 2025 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Signature
/s/ Jennifer Johansson, Attorney-in-fact
Issuer symbol
LRMR
Transactions as of
22 Jan 2025
Net transactions value
$0
Form type
4
Filing time
24 Jan 2025, 16:15:00 UTC
Previous filing
19 Jan 2024
Next filing
27 Jan 2026

Key filing fact

Michael Celano filed Form 4 for Larimar Therapeutics, Inc. (LRMR) on 24 Jan 2025.

Key facts

  • This page summarizes Michael Celano's Form 4 filing for Larimar Therapeutics, Inc. (LRMR).
  • 2 reported transactions and 1 derivative row are listed below.
  • Filing timestamp: 24 Jan 2025, 16:15.

Change

  • Previous filing in this sequence was filed on 19 Jan 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

LRMR transaction

Common Stock

Award

Transaction value
$0
Shares
+34,185
Change %
+24%
Price
$0.000000
Shares after
178,181
Date
22 Jan 2025
Ownership
Direct
Footnotes
F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

LRMR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+205,111
Change %
Price
$0.000000
Shares after
205,111
Date
22 Jan 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
205,111
Exercise price
$3.46
Footnotes
F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F2 The option vests 25% on January 22, 2026, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .